ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,713.64
      1.70%
      US Tech 100
      19,251.20
      -0.43%
      Dow Jones
      42,025.19
      1.26%
      Brent Oil
      73.965
      -0.48%
      Bitcoin
      63,629.42
      1.08%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      09/18/20245:15PMPR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      09/16/20241:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      09/16/20241:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      09/15/20246:36PMBusiness WireRetifanlimab (Zynyz®) von Incyte verlängert progressionsfreies Überleben bei Patienten mit Plattenepithel-Analkarzinom (SCAC) – Datenpräsentation beim ESMO Presidential Symposium 2024NASDAQ:INCYIncyte Corporation
      09/15/20241:34AMBusiness WireINCB123667, l'inhibiteur de la CDK2 d'Incyte, montre des signes prometteurs d'activité clinique chez des patientes atteintes de tumeurs solides avancées, notamment le cancer de l'ovaireNASDAQ:INCYIncyte Corporation
      09/15/20241:34AMBusiness WireIncyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem StadiumNASDAQ:INCYIncyte Corporation
      09/15/202412:48AMBusiness WireLe rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans progression chez les patients atteints de carcinome épidermoïde du canal anal (SCAC) ; des données ont été présentées lors du Symposium présidentiel de l’ESMO 2024NASDAQ:INCYIncyte Corporation
      09/14/202412:45PMBusiness WireIncyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian CancerNASDAQ:INCYIncyte Corporation
      09/14/202410:30AMBusiness WireIncyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential SymposiumNASDAQ:INCYIncyte Corporation
      09/13/20244:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      09/12/20244:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      09/09/20244:30PMBusiness WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
      08/21/20244:49PMBusiness WireIncyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024NASDAQ:INCYIncyte Corporation
      08/21/20244:49PMBusiness WireIncyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO)NASDAQ:INCYIncyte Corporation
      08/21/202411:40AMBusiness WireIncyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024NASDAQ:INCYIncyte Corporation
      08/16/20245:59AMBusiness WireIncyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekanntNASDAQ:INCYIncyte Corporation
      08/16/20245:46AMBusiness WireIncyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaireNASDAQ:INCYIncyte Corporation
      08/15/20244:30PMBusiness WireIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaNASDAQ:INCYIncyte Corporation
      08/15/20244:15PMBusiness WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:INCYIncyte Corporation
      08/15/20246:26AMBusiness WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:INCYIncyte Corporation
      08/14/20245:34PMBusiness WireIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:INCYIncyte Corporation
      08/14/20243:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      08/13/20248:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      08/12/20244:39PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      08/07/20245:00PMBusiness WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
      07/30/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      07/30/20247:00AMBusiness WireIncyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      07/29/20243:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/25/20244:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      07/24/20242:20PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY